Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 3 of Bionano Symposium 2026, entitled OGM Making its Mark in Constitutional Genetic Disorders. Presentations highlighted how ...
The global scar treatment market is growing robustly, expected to be valued at around US$ 23.0 billion in 2026 and projected to reach US$ ...
Non-invasive prenatal testing (NIPT) has recently expanded to include sex chromosomal aneuploidies (SCAs) and copy number variations (CNVs), as well as the commonly screened trisomies (T21, T18, and ...
Molecular testing, including chromosomal microarray analysis, distinguishes between aggressive and indolent kidney cancer subtypes, aiding in accurate diagnosis. Accurate diagnosis is critical for ...
Objective: This study evaluated the utility of single nucleotide polymorphism (SNP) microarray analysis in prenatal genetic assessment of fetuses diagnosed with congenital heart disease (CHD), ...
Of the final sample, 31% of patients received at least one genetic test overall, but only 11% received concordant testing and at least one other test. The current study explored the role of genetic ...
Of the final sample, 31% of patients received at least one genetic test overall, but only 11% received concordant testing and at least one other test. Examining rates of genetic testing for autism ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, announced today that the Applied Biosystems™ CytoScan™ Dx Assay and Applied Biosystems™ ...
Applied Biosystems™ CytoScan™ Dx and Chromosome Analysis Suite (ChAS) Dx software provide complete solution to support cytogenetic testing CARLSBAD, Calif.–(BUSINESS WIRE)–Thermo Fisher Scientific Inc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results